Retension Pharmaceuticals Q3 EPS $(7.33) Misses $(0.75) Estimate
Benzinga Newsdesk 1 day ago
NewsEarningsEarnings Misses
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Retension Pharmaceuticals (NASDAQ:RTSN) reported quarterly losses of $(7.33) per share which missed the analyst consensus estimate of $(0.75) by 877.33 percent. This is a 300.55 percent decrease over losses of $(1.83)
Retension Pharmaceuticals (NASDAQ:RTSN) reported quarterly losses of $(7.33) per share which missed the analyst consensus estimate of $(0.75) by 877.33 percent. This is a 300.55 percent decrease over losses of $(1.83) per share from the same period last year.
